Roswell Park Cancer Institute Appoints New Leadership Team

Get Permission

Kunle Odunsi, MD, PhD, FRCOG, FACOG

Boris Kuvshinoff II, MD, MBA

Victor Filadora, MD, MBA

Thomas Schwaab, MD, PhD

Everett Weiss, MD

Mary Reid, MSPH, PhD

David Goodrich, PhD

Julia Faller, DO, MS

James Mohler, MD

Roswell Park Cancer Institute recently announced a restructuring of its leadership.

“In many cases, these new appointments represent Roswell Park Cancer Institute parlaying our own existing strengths and talents,” says President and CEO Candace Johnson, PhD. “Restructuring some of these positions allows us to use our staff’s critical knowledge in the field to effect the policies and procedures that will enhance and improve our medical and scientific work.”

New appointments to and within the Roswell Park staff included the following:

  • Kunle Odunsi, MD, PhD, ­FRCOG, FACOG, was named Deputy Director of the Institute. Dr. Odunsi provides operational oversight for the scientific, clinical/research, and educational missions of Roswell Park and monitors all research-related initiatives. He is currently the Chair of Gynecologic Oncology, Executive Director of the Center for Immunotherapy, Coleader of the Tumor Immunology and Immunotherapy Program, and the M. Steven Piver Professor of Gynecologic Oncology at the Institute.
  • Boris Kuvshinoff II, MD, MBA, was named Chief Medical Officer. Dr. Kuvshinoff, who continues as Director of the Roswell Park Liver and Pancreas Tumor Center, directs and manages the organization’s medical-affairs strategy, including operational areas such as clinical practice, risk management, physician recruitment, and credentialing. He also manages the Institute’s quality strategy, an ongoing initiative to improve the overall quality of the organization’s facilities and patient-care services.
  • Victor Filadora, MD, MBA, was named Chief of Clinical Services. Dr. Filadora, an anesthesiologist, manages the Ambulatory Services; Perioperative Services; Sterile Processing; Pharmacy, Patient and Family Experience; Endoscopy Services; and Therapeutic Services Programs and will also provide leadership and guidance to clinical department administrators throughout the Institute.
  • Thomas Schwaab, MD, PhD, was named Chief of Strategy, Business Development, and Outreach. Dr. Schwaab, Associate Professor of Oncology and Immunology, supervises the Institute’s business development and overall strategic development and works to continually widen the Institute’s scope of operations and growth potential at national and international levels.
  • Everett Weiss, MD, was named Chief Medical Information Officer. Dr. Weiss promotes and optimizes Roswell Park’s use of electronic health record systems and other clinical information technology to improve the quality, safety, reliability, and efficiency of clinical workflows in the care of patients.
  • Mary Reid, MSPH, PhD, was named Director of Cancer Screening and Survivorship. Dr. Reid, Professor of Oncology in the Department of Medicine, continues her work in Roswell Park’s pioneering Lung Cancer Screening Program and will develop other cancer screening initiatives within the Institute, working with clinical departments to expand the colon and breast screening programs. Dr. Reid is also developing a comprehensive survivorship clinical and outreach program.
  • David Goodrich, PhD, was named Interim Chair of the Department of Pharmacology and Therapeutics. Dr. Goodrich is responsible for supporting the scientific research of departmental faculty and providing leadership in developing research in high-priority fields.
  • Julia Faller, DO, MS, was named Medical Director of Perioperative Services. She provides day-to-day leadership and management of the operations of Roswell Park’s operating rooms, Endoscopy Suite, Post-Anesthesia Care Units, and Surgery Center.
  • James Mohler, MD, was named Associate Director of Cancer Center Support Grant Shared Resources. Dr. Mohler, Senior Vice President of Translational Research, is responsible for overseeing the shared resources funded by the grant program. These resources, which include 14 laboratories, centers, and/or facilities, serve the common needs of cancer researchers. ■